• Prostate cancer: ESMO consensus conference guidelines 2012 

      Horwich, A.; Hugosson, J.; de reijke, T.; Wiegel, T.; Fizazi, K.; Kataja, V.; Parker, C.; Bellmunt, J.; Berthold, D.; Bill-axelson, A.; Carlsson, S.; Daugaard, G.; De meerleer, G.; De reijke, T.; Dearnaley, D.; Fonteyne, V.; Gillessen, S.; Heinrich, D.; Kwiatkowski, M.; Nilsson, S.; Padhani, A.; Papandreou, C.; Roobol, M.; Sella, A.; Valdagni, R.; Van der kwast, T.; Verhagen, P. (2013)
      The first ESMO Consensus Conference on prostate cancer was held in Zurich, Switzerland, on 17-19 November 2011, with the participation of a multidisciplinary panel of leading professionals including experts in methodological ...
    • A systematic review and meta-analysis of interventional studies of bisphosphonates and denosumab in multiple myeloma and future perspectives 

      Chatziravdeli V., Katsaras G.N., Katsaras D., Doxani C., Stefanidis I., Zintzaras E. (2022)
      Bisphosphonates (BPs) and denosumab (DENOS), due to their ability to inhibit osteoclast activity, are used to prevent skeletal complications in multiple myeloma (MM) patients. The NCBI PubMed, Web of Science, Scopus and ...